Fei Shen

Head of BD&L, USA; Global Head of Strategic Partnering, TA Inflammation at Boehringer Ingelheim

Speaker

Fei received her Ph.D. in Neuropharmacology from Loyola University Chicago Stritch School of Medicine and a B.Sc in Biochemistry from East China University Science & Technology. In 2007, she started her industrial career at Theravance Biopharma as an in vivo pharmacologist and led a lab in driving multiple research projects from discovery to Development Candidate nomination and IND filing. In 2015, she joined Boehringer Ingelheim Pharmaceuticals Inc. Global Immunology and Respiratory Disease Research in Ridgefield where she started as a Laboratory Head and became the Head of Pharmacology group in 2016, leading 5 pharmacology labs in moving small molecule, antisense and antibody projects forward in the global Immunology and Respiratory Portfolio. During the 15-year she spent in the R&D organizations, Fei and her teams have contributed two approved products and many assets in the clinical pipeline ranging from ph1 to Ph3. In 2020, she joined the Boehringer Ingelheim Venture Fund USA as an Investment Director and took over the Managing Director role in 2021 to lead the US investment team. Fei has led the formation of multiple newcos and served Board role in ProTgen, Rgenta Therapeutics, ArrePath, xCures, STRM.Bio, Libra, Bodyport and Abexxa Biologics during her tenure at the Venture Fund. In 2026, Fei returned to Boehringer Ingelheim Pharmaceuticals Inc. assuming the leadership roles as Head of BD&L USA and Global Head of TA Inflammation strategic partnership.